Market Tracker

07/01 4:53am ET

Incyte Corp (NASDAQ:INCY)

79.98
Delayed Data
As of Jun 30
 +1.25 / +1.58%
Today’s Change
55.00
Today|||52-Week Range
133.62
-26.25%
Year-to-Date
Why Agenus' Stock Has Stumbled in 2016
Jun 27 / MotleyFool.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close78.74
Today’s open78.88
Day’s range77.85 - 80.43
Volume1,063,029
Average volume (3 months)1,344,788
Market cap$14.4B
Dividend yield--
Data as of 06/30/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-136.25%
Earnings growth (next 5 years)+118.55%
Revenue growth (last year)+47.36%
P/E ratio314.5
Price/Sales26.95
Price/Book83.51

Competitors

 Today’s
change
Today’s
% change
PRGOPerrigo Company PLC-0.88-0.96%
BMRNBiomarin Pharmaceuti...-0.57-0.73%
MDVNMedivation Inc-0.65-1.07%
JAZZJazz Pharmaceuticals...+0.77+0.55%
Data as of 4:00pm ET, 06/30/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.00
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts